Issue 3/2007
Content (14 Articles)
The US Food and Drug Administration: A dysfunctional agency in need of major reforms
- Editor’s Commentary
Steven E. Nissen
Reversing heart failure: The Holy Grail
- Epidemiology and Pathophysiology of Heart Failure
Monica Colvin-Adams
Race-related differences in heart failure therapies: Simply black and white or shades of grey?
- Epidemiology and Pathophysiology of Heart Failure
Gautam R. Shroff, Anne L. Taylor, Monica Colvin-Adams
Safety and efficacy of nesiritide for acute decompensated heart failure: Recent literature and upcoming trials
- Epidemiology and Pathophysiology of Heart Failure
Brian Hiestand, William T. Abraham
Nesiritide for acute decompensated heart failure: Does the benefit justify the risk?
- Epidemiology and Pathophysiology of Heart Failure
Jonathan Sackner-Bernstein, Keith D. Aaronson
The financial burden of destination left ventricular assist device therapy: Who and when?
- Epidemiology and Pathophysiology of Heart Failure
Mark C. Bieniarz, Reynolds Delgado
Right ventricular failure complicating heart failure: Pathophysiology, significance, and management strategies
- Epidemiology and Pathophysiology of Heart Failure
Mobusher Mahmud, Hunter C. Champion
Predicting survival in heart failure
- Epidemiology and Pathophysiology of Heart Failure
Viorel G. Florea, Inder S. Anand
Sustained reversal of left ventricular remodeling following mechanical and pharmacologic therapy
- Management of Heart Failure
Theo E. Meyer
Diagnosis of diastolic heart failure
- Management of Heart Failure
Hidekatsu Fukuta, William C. Little
Prevalence and management of chronotropic incompetence in heart failure
- Management of Heart Failure
Peter H. Brubaker, Dalane W. Kitzman
Role of inflammation in the progression of heart failure
- Management of Heart Failure
Arne Yndestad, Jan Kristian Damås, Erik Øie, Thor Ueland, Lars Gullestad, Pål Aukrust
Glycemic control and treatment patterns in patients with heart failure
- Management of Heart Failure
W. H. Wilson Tang